High-Risk CLL Subgroups See Benefits With Liso-cel - Targeted Oncology

Lisocabtagene maraleucel (liso-cel) improved response outcomes in relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients, with consistent results across high-risk features. Lower tumor burden and fewer prior treatments correlated with better responses. The objective response rate (ORR) and complete response (CR) rates varied by disease characteristics, but overall, liso-cel showed efficacy even in high-risk patients. Inflammatory markers, bulky disease, and lower creatine clearance rates increased the risk of neurological toxicity.